464 related articles for article (PubMed ID: 18661429)
41. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.
Uchil D; Pipalia D; Chawla M; Patel R; Maniar S; Narayani ; Juneja A
J Assoc Physicians India; 2009 Mar; 57():201-4. PubMed ID: 19588647
[TBL] [Abstract][Full Text] [Related]
42. Histological assessment of non-alcoholic fatty liver disease.
Hübscher SG
Histopathology; 2006 Nov; 49(5):450-65. PubMed ID: 17064291
[TBL] [Abstract][Full Text] [Related]
43. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH.
Koike K; Moriya K
J Gastroenterol; 2005 Apr; 40(4):329-36. PubMed ID: 15868369
[TBL] [Abstract][Full Text] [Related]
44. Impact of steatosis on insulin secretion in chronic hepatitis C patients.
Narita R; Abe S; Tabaru A; Otsuki M
Am J Gastroenterol; 2007 Oct; 102(10):2173-80. PubMed ID: 17680843
[TBL] [Abstract][Full Text] [Related]
45. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
46. Insulin resistance: a metabolic pathway to chronic liver disease.
Bugianesi E; McCullough AJ; Marchesini G
Hepatology; 2005 Nov; 42(5):987-1000. PubMed ID: 16250043
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.
Sanyal AJ
Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):46-53. PubMed ID: 16265100
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis C and diabetes: one treatment for two diseases?
Pattullo V; Heathcote J
Liver Int; 2010 Mar; 30(3):356-64. PubMed ID: 20040049
[TBL] [Abstract][Full Text] [Related]
49. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
Tarantino G; Saldalamacchia G; Conca P; Arena A
J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757
[TBL] [Abstract][Full Text] [Related]
50. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
51. [Non-alcoholic fatty liver disease in children: a new complication of obesity].
Bocca G; Stolk RP; Scheenstra R; Sauer PJ
Ned Tijdschr Geneeskd; 2008 Nov; 152(45):2443-7. PubMed ID: 19051794
[TBL] [Abstract][Full Text] [Related]
52. Evolving trends in nonalcoholic fatty liver disease.
Delgado JS
Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data.
Serfaty L; Capeau J
Liver Int; 2009 Mar; 29 Suppl 2():13-25. PubMed ID: 19187069
[TBL] [Abstract][Full Text] [Related]
54. Hepatitis C infection and nonalcoholic fatty liver disease.
Cheung O; Sanyal AJ
Clin Liver Dis; 2008 Aug; 12(3):573-85, viii-ix. PubMed ID: 18625429
[TBL] [Abstract][Full Text] [Related]
55. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C.
Younossi ZM; Afendy A; Stepanova M; Hossain N; Younossi I; Ankrah K; Gramlich T; Baranova A
Liver Int; 2009 Oct; 29(9):1403-12. PubMed ID: 19515216
[TBL] [Abstract][Full Text] [Related]
56. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.
Targher G; Chonchol M; Miele L; Zoppini G; Pichiri I; Muggeo M
Semin Thromb Hemost; 2009 Apr; 35(3):277-87. PubMed ID: 19452403
[TBL] [Abstract][Full Text] [Related]
57. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis.
Schuppan D; Gorrell MD; Klein T; Mark M; Afdhal NH
Liver Int; 2010 Jul; 30(6):795-808. PubMed ID: 20624207
[TBL] [Abstract][Full Text] [Related]
58. Nonalcoholic fatty liver disease as a complication of insulin resistance.
Abdelmalek MF; Diehl AM
Med Clin North Am; 2007 Nov; 91(6):1125-49, ix. PubMed ID: 17964913
[TBL] [Abstract][Full Text] [Related]
59. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
60. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
Targher G
Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
